Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
La Crosse encephalitis (CE) is an acute arboviral infection caused by the La Crosse bunyavirus transmitted by an infected mosquito, usually observed in infants, children or adolescents (6 months to 16 years), and characterized by the onset of flulike symptoms such as fever, chills, nausea, vomiting, headache, and abdominal pain, followed by the onset of encephalitis characterized by somnolence, obtundation, and even seizures, focal neurologic signs (asymmetrical reflexes or Babinski signs), paralysis or even coma. CE can leave sequelae such as residual epilepsy and neurocognitive deficits.
Biomarker and diagnostic research for la Crosse encephalitis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for la Crosse encephalitis.
14 publications have been identified in PubMed for la Crosse encephalitis. Research spans Epidemiology / Natural History (43%), Basic Science / Preclinical (29%), and Diagnostic / Biomarker (7%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 6 | 43% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research
4 |
29% |
Testing and diagnosis research | 1 | 7% |
Research summaries | 1 | 7% |
Patient case studies | 1 | 7% |
New treatment approaches | 1 | 7% |
Nishiduka E (2026). [PMID: 41882526](https://pubmed.ncbi.nlm.nih.gov/41882526/). *BMC Genomics*. [Basic Science / Preclinical]
Iankov I (2026). [PMID: 41407241](https://pubmed.ncbi.nlm.nih.gov/41407241/). *Virus research*. [Basic Science / Preclinical]
Shariati F (2025). [PMID: 40084509](https://pubmed.ncbi.nlm.nih.gov/40084509/). *Journal of the Pediatric Infectious Diseases Society*. [Diagnostic / Biomarker]
Singh PG (2025). [PMID: 40986408](https://pubmed.ncbi.nlm.nih.gov/40986408/). *Military medicine*. [Case Report / Case Series]
Konishi K (2025). [PMID: 40698821](https://pubmed.ncbi.nlm.nih.gov/40698821/). *Antimicrobial agents and chemotherapy*. [Epidemiology / Natural History]
Day CA (2025). [PMID: 39441803](https://pubmed.ncbi.nlm.nih.gov/39441803/). *Journal of medical entomology*. [Epidemiology / Natural History]
Subbiah J (2025). [PMID: 40162770](https://pubmed.ncbi.nlm.nih.gov/40162770/). *Microbiology spectrum*. [Gene Therapy / Novel Therapeutics]
Sankhe S (2025). [PMID: 40143333](https://pubmed.ncbi.nlm.nih.gov/40143333/). *Viruses*. [Epidemiology / Natural History]
Woods TA (2025). [PMID: 40133033](https://pubmed.ncbi.nlm.nih.gov/40133033/). *Emerging infectious diseases*. [Epidemiology / Natural History]
Li ZA (2024). [PMID: 38331257](https://pubmed.ncbi.nlm.nih.gov/38331257/). *Virus research*. [Epidemiology / Natural History]